ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial †
Titel:
ABVD (8 cycles) versus BEACOPP (4 escalated cycles ≥4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0–2) of the LYSA H34 randomized trial †
Auteur:
Mounier, N. Brice, P. Bologna, S. Briere, J. Gaillard, I. Heczko, M. Gabarre, J. Casasnovas, O. Jaubert, J. Colin, P. Delmer, A. Devidas, A. Bachy, E. Nicolas-Virelizier, E. Aoudjhane, A. Humbrecht, C. Andre, M. Carde, P.